BR102021016873A2 - Use of ambenium to inhibit coronavirus proteases, with application in the fight against coronaviruses - Google Patents
Use of ambenium to inhibit coronavirus proteases, with application in the fight against coronavirusesInfo
- Publication number
- BR102021016873A2 BR102021016873A2 BR102021016873A BR102021016873A BR102021016873A2 BR 102021016873 A2 BR102021016873 A2 BR 102021016873A2 BR 102021016873 A BR102021016873 A BR 102021016873A BR 102021016873 A BR102021016873 A BR 102021016873A BR 102021016873 A2 BR102021016873 A2 BR 102021016873A2
- Authority
- BR
- Brazil
- Prior art keywords
- coronavirus
- proteases
- application
- inhibit
- ambenium
- Prior art date
Links
- 241000711573 Coronaviridae Species 0.000 title abstract 8
- 102000035195 Peptidases Human genes 0.000 title abstract 3
- 108091005804 Peptidases Proteins 0.000 title abstract 3
- 239000004365 Protease Substances 0.000 title abstract 3
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 abstract 3
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 2
- 229960000451 ambenonium Drugs 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 101800000535 3C-like proteinase Proteins 0.000 abstract 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 abstract 1
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 1
- 108010022752 Acetylcholinesterase Proteins 0.000 abstract 1
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 229940022698 acetylcholinesterase Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229920002521 macromolecule Polymers 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 206010028417 myasthenia gravis Diseases 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
uso do ambenônio para inibição de proteases de coronavírus, com aplicação no combate a coronaviroses. a presente invenção refere-se ao uso do medicamento ambenônio (db01122) como potencial inibidor de proteases de coronavírus, macromolécula essencial no ciclo reprodutivo da família de vírus causadores de infecções, principalmente respiratórias. o ambenônio é usado, atualmente, no tratamento da doença muscular myasthenia gravis, por ser um inibidor de acetilcolinesterase, principalmente receptores muscarínico e nicotínico. a proposta do atual pedido de patente foi baseada em estudos computacionais de uma representante do grupo das main proteases de coronavírus, a 3clpro de sars-cov-2. foi verificado que existe potencial de inibição do fármaco em relação à atividade da 3clpro viral, e consequentemente seu uso no tratamento da covid-19, coronaviroses e infecções respiratórias causadas pelo coronavírus.use of ambenium to inhibit coronavirus proteases, with application in the fight against coronaviruses. The present invention refers to the use of the drug ambenonium (db01122) as a potential inhibitor of coronavirus proteases, an essential macromolecule in the reproductive cycle of the family of viruses that cause infections, mainly respiratory infections. Ambenonium is currently used in the treatment of the muscular disease myasthenia gravis, as it is an inhibitor of acetylcholinesterase, mainly muscarinic and nicotinic receptors. The proposal for the current patent application was based on computational studies of a representative of the group of coronavirus main proteases, 3clpro of sars-cov-2. it was verified that there is potential for the drug to inhibit the activity of viral 3clpro, and consequently its use in the treatment of covid-19, coronaviruses and respiratory infections caused by the coronavirus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021016873A BR102021016873A2 (en) | 2021-08-25 | 2021-08-25 | Use of ambenium to inhibit coronavirus proteases, with application in the fight against coronaviruses |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102021016873A BR102021016873A2 (en) | 2021-08-25 | 2021-08-25 | Use of ambenium to inhibit coronavirus proteases, with application in the fight against coronaviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR102021016873A2 true BR102021016873A2 (en) | 2021-12-07 |
Family
ID=90824142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR102021016873A BR102021016873A2 (en) | 2021-08-25 | 2021-08-25 | Use of ambenium to inhibit coronavirus proteases, with application in the fight against coronaviruses |
Country Status (1)
| Country | Link |
|---|---|
| BR (1) | BR102021016873A2 (en) |
-
2021
- 2021-08-25 BR BR102021016873A patent/BR102021016873A2/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
| BR112022019557A2 (en) | NOROVIRUS AND CORONAVIRUS REPLICATION INHIBITORS | |
| CO2022015415A2 (en) | Antiviral application of nucleoside analogue or combination formulation containing nucleoside analogue | |
| BR112022026899A2 (en) | COMPOUND REPRESENTED BY FORMULA (I) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A VIRAL INFECTION, METHOD OF INHIBITING VIRAL PROTEASE 3C OR VIRAL PROTEASE 3CL IN A MAMMAL, AND METHOD OF TREATMENT OF A DISORDER RESPIRATORY | |
| BR112015025766A2 (en) | highly active nucleoside derivative for the treatment of hcv | |
| BR112015029491A2 (en) | imidazopyrrolidinone derivatives and their use in the treatment of disease | |
| BR112019008431A2 (en) | application of norcetamine (s) and salt thereof as a drug | |
| WO2005020884A3 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| BR112015029512A2 (en) | pyrazolopyrrolidine derivatives and their use in the treatment of diseases | |
| BR112015012197A8 (en) | cdk mtor inhibitor uses, and pharmaceutical combination comprising the same | |
| BR112014011670A2 (en) | anti-adrenomedulin (adm) antibody or anti-adm antibody fragment or non-ig anti-adm structure for use in therapy | |
| BR112013027554A2 (en) | "uses of compounds in the treatment of alzheimer's disease, huntington's disease, autism and other disorders" | |
| BR112013027670A2 (en) | "Amide compound, pharmaceutical composition and medicament comprising it and rory antagonist" | |
| BR112014025711A8 (en) | compound, medicine, and use of a compound | |
| MX2022016405A (en) | 1'-cyano nucleoside analogs and uses thereof. | |
| WO2022217154A3 (en) | Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses | |
| BR112014002860A2 (en) | pasteurellaceae vaccines | |
| BR112023002951A2 (en) | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | |
| BR112021026397A2 (en) | ep2 antagonist | |
| BR112016013961A2 (en) | angiotensin ii alone or in combination for the treatment of hypotension | |
| BR112022017923A2 (en) | CORONA VIRUS INFECTION TREATMENT | |
| EA201991147A1 (en) | TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM USING sGC STIMULANTS | |
| BR0206237A (en) | Use of a carbostyril compound | |
| BR112019022307A2 (en) | PIRROLOPYRIMIDINE DERIVATIVES USEFUL AS INFLUENCE VIRUS REPLICATION INHIBITORS. | |
| BR112022010798A2 (en) | PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVE, ITS USE AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03B | Publication of an application: publication anticipated [chapter 3.2 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |